Literature DB >> 21987779

Antibody-dependent enhancement of Marburg virus infection.

Eri Nakayama1, Daisuke Tomabechi, Keita Matsuno, Noriko Kishida, Reiko Yoshida, Heinz Feldmann, Ayato Takada.   

Abstract

BACKGROUND: Marburg virus (MARV) and Ebola virus (EBOV) cause severe hemorrhagic fever in primates. Earlier studies demonstrated that antibodies to particular epitopes on the glycoprotein (GP) of EBOV enhanced virus infectivity in vitro.
METHODS: To investigate this antibody-dependent enhancement (ADE) in MARV infection, we produced mouse antisera and monoclonal antibodies (mAbs) to the GPs of MARV strains Angola and Musoke.
RESULTS: The infectivity of vesicular stomatitis virus pseudotyped with Angola GP in K562 cells was significantly enhanced in the presence of Angola GP antisera, whereas only minimal ADE activity was seen with Musoke GP antisera. This difference correlated with the percentage of hybridoma clones producing infectivity-enhancing mAbs. Using mAbs to MARV GP, we identified 3 distinct ADE epitopes in the mucinlike region on Angola GP. Interestingly, some of these antibodies bound to both Angola and Musoke GPs but showed significantly higher ADE activity for strain Angola. ADE activity depended on epitopes in the mucinlike region and glycine at amino acid position 547, present in the Angola but absent in the Musoke GP.
CONCLUSIONS: These results suggest a possible link between ADE and MARV pathogenicity and provide new insights into the mechanisms underlying ADE entry of filoviruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987779      PMCID: PMC3189991          DOI: 10.1093/infdis/jir334

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

Review 2.  Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.

Authors:  Ayato Takada; Yoshihiro Kawaoka
Journal:  Rev Med Virol       Date:  2003 Nov-Dec       Impact factor: 6.989

3.  Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein.

Authors:  Dana L Swenson; Kelly L Warfield; Kathleen Kuehl; Thomas Larsen; Michael C Hevey; Alan Schmaljohn; Sina Bavari; M Javad Aman
Journal:  FEMS Immunol Med Microbiol       Date:  2004-01-15

4.  Marburg-virus disease in Kenya.

Authors:  D H Smith; B K Johnson; M Isaacson; R Swanapoel; K M Johnson; M Killey; A Bagshawe; T Siongok; W K Keruga
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

5.  Marburg virus disease.

Authors:  G A Martini
Journal:  Postgrad Med J       Date:  1973-08       Impact factor: 2.401

6.  Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies.

Authors:  Eri Nakayama; Ayaka Yokoyama; Hiroko Miyamoto; Manabu Igarashi; Noriko Kishida; Keita Matsuno; Andrea Marzi; Heinz Feldmann; Kimihito Ito; Masayuki Saijo; Ayato Takada
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

7.  Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.

Authors:  Takeshi Noda; Hiroshi Sagara; Emiko Suzuki; Ayato Takada; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Outbreake of Marburg virus disease in Johannesburg.

Authors:  J S Gear; G A Cassel; A J Gear; B Trappler; L Clausen; A M Meyers; M C Kew; T H Bothwell; R Sher; G B Miller; J Schneider; H J Koornhof; E D Gomperts; M Isaäcson; J H Gear
Journal:  Br Med J       Date:  1975-11-29

9.  Antibody-dependent enhancement of Ebola virus infection.

Authors:  Ayato Takada; Heinz Feldmann; Thomas G Ksiazek; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo.

Authors:  Daniel G Bausch; Matthias Borchert; Thomas Grein; Cathy Roth; Robert Swanepoel; Modeste L Libande; Antoine Talarmin; Eric Bertherat; Jean-Jacques Muyembe-Tamfum; Ben Tugume; Robert Colebunders; Kader M Kondé; Patricia Pirad; Loku L Olinda; Guénaël R Rodier; Patricia Campbell; Oyewale Tomori; Thomas G Ksiazek; Pierre E Rollin
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

View more
  27 in total

1.  Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.

Authors:  Makoto Kuroda; Daisuke Fujikura; Asuka Nanbo; Andrea Marzi; Osamu Noyori; Masahiro Kajihara; Junki Maruyama; Keita Matsuno; Hiroko Miyamoto; Reiko Yoshida; Heinz Feldmann; Ayato Takada
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

2.  Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Authors:  Natalia A Kuzmina; Patrick Younan; Pavlo Gilchuk; Rodrigo I Santos; Andrew I Flyak; Philipp A Ilinykh; Kai Huang; Ndongala M Lubaki; Palaniappan Ramanathan; James E Crowe; Alexander Bukreyev
Journal:  Cell Rep       Date:  2018-08-14       Impact factor: 9.423

3.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

4.  Mapping of conserved and species-specific antibody epitopes on the Ebola virus nucleoprotein.

Authors:  Katendi Changula; Reiko Yoshida; Osamu Noyori; Andrea Marzi; Hiroko Miyamoto; Mari Ishijima; Ayaka Yokoyama; Masahiro Kajihara; Heinz Feldmann; Aaron S Mweene; Ayato Takada
Journal:  Virus Res       Date:  2013-05-20       Impact factor: 3.303

5.  Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.

Authors:  Masahiro Kajihara; Eri Nakayama; Andrea Marzi; Manabu Igarashi; Heinz Feldmann; Ayato Takada
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

Review 6.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

7.  Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus.

Authors:  Junki Maruyama; Hiroko Miyamoto; Masahiro Kajihara; Hirohito Ogawa; Ken Maeda; Yoshihiro Sakoda; Reiko Yoshida; Ayato Takada
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

8.  Serological evidence of Ebola virus infection in Indonesian orangutans.

Authors:  Chairul A Nidom; Eri Nakayama; Reviany V Nidom; Mohamad Y Alamudi; Syafril Daulay; Indi N L P Dharmayanti; Yoes P Dachlan; Mohamad Amin; Manabu Igarashi; Hiroko Miyamoto; Reiko Yoshida; Ayato Takada
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

9.  Cellular factors implicated in filovirus entry.

Authors:  Suchita Bhattacharyya; Thomas J Hope
Journal:  Adv Virol       Date:  2013-01-13

Review 10.  Potential vaccines and post-exposure treatments for filovirus infections.

Authors:  Brian M Friedrich; John C Trefry; Julia E Biggins; Lisa E Hensley; Anna N Honko; Darci R Smith; Gene G Olinger
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.